Requirements for cell rounding and surface protein down-regulation by Ebola virus glycoprotein.
Ebola virus causes an acute hemorrhagic fever that is associated with high morbidity and mortality. The viral glycoprotein is thought to contribute to pathogenesis, though precise mechanisms are unknown. Cellular pathogenesis can be modeled in vitro by expression of the Ebola viral glycoprotein (GP) in cells, which causes dramatic morphological changes, including cell rounding and surface protein down-regulation. These effects are known to be dependent on the presence of a highly glycosylated region of the glycoprotein, the mucin domain. Here we show that the mucin domain from the highly pathogenic Zaire subtype of Ebola virus is sufficient to cause characteristic cytopathology when expressed in the context of a foreign glycoprotein. Similarly to full length Ebola GP, expression of the mucin domain causes rounding, detachment from the extracellular matrix, and the down-regulation of cell surface levels of beta1 integrin and major histocompatibility complex class 1. These effects were not seen when the mucin domain was expressed in the context of a glycophosphatidylinositol-anchored isoform of the foreign glycoprotein. In contrast to earlier analysis of full length Ebola glycoproteins, chimeras carrying the mucin domains from the Zaire and Reston strains appear to cause similar levels of down-modulation and cell detachment. Cytopathology associated with Ebola glycoprotein expression does not occur when GP expression is restricted to the endoplasmic reticulum. In contrast to a previously published report, our results demonstrate that GP-induced surface protein down-regulation is not mediated through a dynamin-dependent pathway. Overall, these results support a model in which the mucin domain of Ebola GP acts at the cell surface to induce protein down modulation and cytopathic effects.
Francica
Joseph R
JR
Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, 19104-6076, USA.
Matukonis
Meghan K
MK
Bates
Paul
P
D048430:Cell Shape; D015023:Democratic Republic of the Congo; D015536:Down-Regulation; D029043:Ebolavirus / Q000502:physiology*; D004847:Epithelial Cells / Q000473:pathology* / Q000821:virology; D006367:HeLa Cells; D015395:Histocompatibility Antigens Class I / Q000096:biosynthesis*; D006801:Humans; D019012:Integrin beta1 / Q000096:biosynthesis*; D008954:Models, Biological; D017434:Protein Structure, Tertiary; D014759:Viral Envelope Proteins / Q000235:genetics / Q000378:metabolism*
D015395:Histocompatibility Antigens Class I; D019012:Integrin beta1; D014759:Viral Envelope Proteins; C113189:envelope glycoprotein, Ebola virus